If you are basing that on a simple "snapshot" you're missing a lot. The problem is that you aren't seeing the big picture. As with Vimovo, the new product (Actimmune) was under-promoted. If HZNP holds with the BTB marketing approach (augmented by the existing sales force) the current $40M in sales could be $80-100M within a year, offsetting the $200M cash outlay within 2-3 years). Additionally the rather significant tax advantages of migrating to Ireland will be a huge boost to the net for all four products.
The Q1 Earnings CC and the investors conference on 3/28 are going to be extremely interesting. I wouldn't start calling trends just yet.